Back

Sodium-glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Treatment of transthyretin amyloidosis Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Mr William Jakymiu Furtado

University Center of the Educational Foundation of Brusque, Brusque (Brazil)

7 More presentations in this session

Presentation thumbnail
Relative efficacy of tafamidis, acoramidis, patisiran and vutrisiran in patients with transthyretin cardiac amyloidosis: a network meta-analysis
Doctor V. Castiglione (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Optimizing treatment strategies for transthyretin amyloid cardiomyopathy: a comprehensive Bayesian network meta-analysis of disease-specific therapies
Doctor M. Rahman (Flushing, US)
Abstract Slides Video
Presentation thumbnail
Diagnostic, therapeutic and prognostic implications of carpal tunnel syndrome and spinal stenosis in wild-type transthyretin cardiac amyloidosis.
Doctor P. Debonnaire (Brugge, BE)
Abstract Slides Video
Presentation thumbnail
Effects of targeted transthyretin amyloid cardiomyopathy treatments on clinical outcomes a meta-analysis
Doctor T. Tsampras (Athens, GR)
Abstract Slides Video
Presentation thumbnail
Which patients did recent trials in transthyretin amyloid cardiomyopathy select? - insights from a prospective patient registry
Doctor L. Schmid (Vienna, AT)
Abstract Slides Video

Access the full session

Session thumbnail
Treatment of transthyretin amyloidosis

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
SGLT2 inhibitors in wild-type transthyretin amyloid cardiomyopathy: what to expect?
thumbnail
Congress Presentation
SGLT2i on transthyretin amyloid cardiomyopathy - a new drug for an under-recognized cardiomyopathy
thumbnail
Congress Presentation
Conventional medical therapies in patients with heart failure across different risk for transthyretin amyloid cardiomyopathy in the DELIVER, PARAGON-HF and TOPCAT Americas trials

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources